Evidence map›Paper›PMID 38541809›Full record

ReviewJournal of clinical medicine2024

Nimesulide-Induced Fixed Drug Eruption Followed by Etoricoxib-Induced Fixed Drug Eruption: An Unusual Case Report and Review of the Literature.

Michael Makris, Niki Papapostolou, Ioannis-Alexios Koumprentziotis, Georgia Pappa, Alexander C Katoulis

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Etoricoxib-Induced Fixed Erythema.Journal of clinical medicine · 2025
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Michael MakrisAllergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0003-2713-2380
Niki PapapostolouAllergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0003-3950-3089
Ioannis-Alexios KoumprentziotisAllergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0002-1156-7139
Georgia Pappa2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0001-6932-1441
Alexander C Katoulis2nd Department of Dermatology and Venereology, Medical School, "Attikon" University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0001-8189-7486
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fixed drug eruption (FDE) is a well-recognized, non-immediate, drug hypersensitivity reaction, often attributed to the use of various medications, most commonly non-steroidal anti-inflammatory drugs (NSAIDs) and antibiotics. Cross-reactivity between related NSAIDs in FDE has been reported, but among chemically unrelated NSAIDs, is rare. Herein, we present a rare well-documented case where a patient initially displayed tolerance to etoricoxib after experiencing a nimesulide-induced FDE. Subsequently, the patient developed an etoricoxib-induced FDE, accompanied by the development of bullous lesions. This case report and the literature review on comparable FDE occurrences shed light on the intricate nature of FDEs, suggesting the possibility of cross-reactivity between chemically related and unrelated NSAIDs or the emergence of new drug-specific T cells without cross-reactivity after multiple exposures to a drug in a susceptible patient. Our case underscores the importance of increased awareness and vigilance among both physicians and patients in the realm of personalized medicine. Further research is needed to unravel the intricate mechanisms behind these drug eruptions, improve diagnostic approaches, and enhance patient care.

Indexed as

cross-reactivitycutaneous drug reactionetoricoxibfixed drug eruption (FDE)hypersensitivity reactionnimesulidenon-steroidal anti-inflammatory drugs (NSAIDs)

Identifiers

PMID38541809
PMCPMC10971142
OpenAlexW4392661183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.